US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

April 13, 2018: By Jon Swedien
IDx-DR artificial intelligence diagnostic system

IDx-DR artificial intelligence diagnostic system

The FDA has granted IDx’ De Novo request to market the IDx-DR, an artificial intelligence (AI) diagnostic system for the autonomous detection of diabetic retinopathy, the agency announced April 12.

IDx-DR is the first autonomous, AI-based diagnostic system the FDA has authorized for commercialization, the agency said.

IDx-DR is designed to provide an immediate, reliable screening test for diabetic retinopathy, including macular edema, during a routine office visit in a primary care setting, Iowa-based IDx said. The IDx-DR makes an assessment without the need for a clinician to also interpret the image or results, making it usable by health care providers not normally involved in eye care, the company said.

“Early detection of retinopathy is an important part of managing care for the millions of people with diabetes, yet many patients with diabetes are not adequately screened for diabetic retinopathy since about 50 percent of them do not see their eye doctor on a yearly basis,” said Malvina Eydelman, MD, director of the FDA’s Division of Ophthalmic and Ear, Nose, and Throat Devices.

The exam is performed on site in minutes and produces a diagnostic interpretation and associated report, including care instructions that are aligned with American Academy of Ophthalmology guidelines for diabetic retinopathy, IDx said.

This enables primary care providers to counsel patients on follow-up care while they are still in the office, the company said.

IDx-DR received expedited review under the FDA’s Breakthrough Devices program following a pivotal clinical trial conducted at 10 primary care sites across the US, the company said.

IDx-DR is intended for use by health care providers to automatically detect more than mild diabetic retinopathy in adults above age 22 who are diagnosed with diabetes and have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400, IDx said.

A team of ophthalmologists at the University of Iowa Hospitals and Clinics founded IDx in 2010. The IDx-DR is the company’s first product.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023